France· FR:64911770
IMATINIB EG 100 mg, comprimé pelliculé sécable
A medicinal product containing mésilate d'imatinib, registered in France by EG LABO - LABORATOIRES EUROGENERICS, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MÉSILATE D'IMATINIB
- Manufacturer
- EG LABO - LABORATOIRES EUROGENERICS
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009300263661 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 60 comprimé(s)EUR 307.79
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mésilate d'imatinib in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaGLIVECNovartis Europharm Limited, Dublin
- United Statesimatinib mesylateSun Pharmaceutical Industries, Inc.
- NetherlandsBimatix 100 mg filmomhulde tablettenStada Arzneimittel AG
- FinlandBimatixSTADA Arzneimittel AG
- BelgiumGlivec 100 mgNovartis Europharm
- SwitzerlandGlivec
- SpainGLIVEC 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- SwedenBimatix 100 mg Filmdragerad tablettSTADA Arzneimittel AG
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Imagerolan, Imatinib 1a Pharma
- Belgium · Imatinib Eg, Imatinib Grindeks
- Bulgaria · Иматиниб Тева Фарма, Меаксин
- Cyprus · Imarem, Imatinib Koanaa 100 Mg
- Czechia · Imanivec, Imatinib Grindeks
- Germany · Imanivec, Imatinib 1 A Pharma
- Denmark · Bimatix, Imatinib "sandoz"
- Estonia · Glipox, Imatinib Grindeks
- Spain · Imatinib Cipla, Imatinib Farmalider
- Finland · Bimatix, Imatinib Hexal
- United Kingdom (Northern Ireland) · Imatinib, Imatinib Amarox
- Greece · Imatek, Imatinib Aenorasis
- Croatia · Imakrebin, Meaxin
- Hungary · Imaniver, Imatinib 1 A Pharma
- Ireland · Imatinib Krka D.D., Imatinib Rowex
- Iceland · Bimatix, Glivec
- Italy · Imanivec, Imatinib Dr. Reddy’s
- Liechtenstein · Glivec, Imatinib Accord
- Lithuania · Glipox, Imatinib Grindeks
- Luxembourg · Imatinib, Imatinib Eg
- Latvia · Imatinib Grindeks, Imatinib Inteli
- Malta · Imatinib Tad, Nibix
- Netherlands · Bimatix, Imakrebin
- Norway · Bimatix, Glivec
- Poland · Imatenil, Meaxin
- Portugal · Imatinib Aurobindo, Imatinib Aurovitas
- Romania · Imakrebin, Imatinib Grindeks
- Sweden · Bimatix, Imatinib Amarox
- Slovenia · Meaxin
- Slovakia · Imatinib Glenmark, Imatinib Grindeks
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b61dcd0f-04cf-4fe6-9d84-e32b0fbd9ac8 GET /v1/drugs/b61dcd0f-04cf-4fe6-9d84-e32b0fbd9ac8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64911770",
"date_amm": "2016-09-05",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"substance": "MÉSILATE D'IMATINIB",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "comprimé pelliculé sécable",
"voies_administration": "orale",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about mésilate d'imatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.